[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
[PDF][PDF] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - core.ac.uk
Objectives: Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
[引用][C] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - cir.nii.ac.jp
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive
non-small cell lung cancer: Interim analysis of a Phase 3b study | CiNii Research CiNii 国立 …
non-small cell lung cancer: Interim analysis of a Phase 3b study | CiNii Research CiNii 国立 …
[引用][C] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, A Passaro, KK Laktionov, A Poltoratskiy… - Lung Cancer, 2021 - elibrary.ru
This work was supported by Boehringer Ingelheim Inc. The study sponsor participated in the
design of the studies, the collection, analysis, and interpretation of the data, writing this …
design of the studies, the collection, analysis, and interpretation of the data, writing this …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy… - Lung …, 2021 - lungcancerjournal.info
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov… - Lung cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
F de Marinis, KK Laktionov, A Poltoratskiy… - Lung Cancer …, 2020 - europepmc.org
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
[PDF][PDF] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung …, 2021 - academia.edu
Objectives: Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
M Filippo, KK Laktionov, A Poltoratskiy, I Egorova… - LUNG CANCER, 2021 - iris.unito.it
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
[PDF][PDF] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - iris.unito.it
Objectives: Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …